DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Single-dose Azithromycin for the Treatment of Yaws

Information source: Lihir Medical Centre
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Yaws; Treponema Infection; Neglected Tropical Disease

Intervention: Penicillin-G-benzathine (Drug); Azithromycin (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Lihir Medical Centre

Official(s) and/or principal investigator(s):
Quique Bassat, MD, PhD, Study Director, Affiliation: Centre for International Health Research/Hospital ClĂ­nic/University of barcelona

Summary

Yaws, an endemic treponematosis and as such a neglected tropical disease (NTD), is currently making a comeback in children in rural areas. Injectable long acting penicillin remains the drug of choice for the treatment of yaws. However, on the basis of successful experience with venereal syphilis in large-scale studies, oral azithromycin has emerged as a potential alternative that overcomes the major medical and logistic disadvantages of the current regimen. In this non-inferiority randomized clinical trial the investigators propose a comparable scheme for the treatment of yaws, to test the efficacy of a single, oral dose of azithromycin versus a single, i. m. dose of benzathine penicillin G. Sample size has been calculated to detect a non-inferiority margin of 10%. Children < 15 years of age with a confirmed diagnosis of yaws will be randomly assigned to receive 30mg/Kg (maximum 2g) of azithromycin orally or 50. 000units/Kg (maximum 2. 4MU) of penicillin-G-benzathine intramuscularly. The primary outcome is treatment efficacy, with cure defined serologically (a decline in the VDRL titer of at least two dilutions by six months after treatment) and, in primary yaws, also by epithelialization of ulcers within two weeks.

Clinical Details

Official title: Single-dose Azithromycin Versus Penicillin G Benzathine for the Treatment of Yaws in Children

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Serologic cure

Secondary outcome:

clinical cure

3 months cure rate

Detailed description:

Regulatory status: Investigational - Randomized Clinical Trial. Registered product for

antibacterial therapy BACKGROUND Penicillin remains the drug of choice for the treatment of endemic treponematoses including yaws. This type of treatment is effective and cheap. There are, however, some disadvantages: the pain associated with a large volume (4 ml) deep i. m. injection, a high prevalence of self-reported allergy to penicillin, structural and logistic problems related to a treatment based on injection of drugs. Azithromycin, a macrolide antibiotic with a long (68 hours) half-life in tissue and proven efficacy against T. pallidum is a promising candidate. In two randomized trials, for the treatment of syphilis in adults, a single 2-g oral dose of azithromycin achieved cure rates equivalent to that of standard treatment with 2. 4 MU of penicillin G benzathine. On the basis of experience with venereal syphilis, azithromycin has emerged as an alternative treatment for Yaws. It represents a more accessible treatment as it could be prescribed by village health workers and therefore enable yaws control to be more easily incorporated into other primary health-care programmes. The product is available as an oral tablet to be administered at a single dose of 30mg/Kg in children and 2 g in adults. Safety and efficacy using azithromycin 30 mg/kg given as a single dose in the treatment of pediatric patients over 6 months of age with otitis media have been established and approved by the FDA. INFORMED CONSENT All participants (or their guardian or parents) who are eligible for enrolment in the trial according to biological and demographic inclusion criteria are provided with detailed information on the purpose of the trial and on risks and benefits of participation, according to information listed in an information sheet. Consent is provided in writing. SAMPLE SIZE JUSTIFICATION The sample size would be 244; It was calculated on the basis of a non-inferiority trial design and the following assumptions: Statistical power of 80 percent;to exclude the possibility that the absolute efficacy of azithromycin was at least 10% percent less than that of penicillin; 5% significance level using a one-sided equivalence test of proportions; assuming that the true efficacy of each agent was equivalent at 95 percent and that approximately 10 percent of participants would be lost to follow-up. RANDOMIZATION PROCEDURE A random allocation schedule, stratified according to study group, will be generated centrally with the use of blocked randomization, random permuted blocks of four, and a 1: 1 allocation ratio. The allocation will be concealed from investigators through the use of sequentially numbered, sealed envelopes

Eligibility

Minimum age: 6 Months. Maximum age: 15 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- All children 6 months to 15 years of age who present to LMC with suggestive skin

lesions or joint pains and VDRL and TPHA testing are positive

- Suggestive skin lesions defined as: Symptomatic > 4 weeks, painless, a traumatic

ulcers with raised margins. VDRL positive when titer of at least 1: 16 Exclusion Criteria:

- Pregnancy

- Less than 6 months of age

- Known allergy to penicillin or macrolide

- Use of antibiotics active against treponema during the preceding six months

(penicillin-G-benzathine, ceftriaxone, azithromycin or doxycycline)

Locations and Contacts

Lihir Medical Centre, Kavieng, New Ireland Province 034, Papua New Guinea
Additional Information

Starting date: September 2010
Last updated: April 11, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017